Alkermes plc (ALKS) P/E Ratio History
UndervaluedTrading at 38.6x vs 5Y avg 71.8x · 70th percentile · Below historical baseline · Data 2006–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Alkermes plc (ALKS) trades at a price-to-earnings ratio of 38.6x, with a stock price of $55.22 and trailing twelve-month earnings per share of $0.92.
The current P/E is 46% below its 5-year average of 71.8x. Over the past five years, ALKS's P/E has ranged from a low of 8.1x to a high of 467.1x, placing the current valuation at the 70th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, ALKS trades at a 65% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, ALKS commands a significant premium over the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ALKS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ALKS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ALKS P/E vs Peers
Commercial Specialty Pharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.7Lowest | 0.65 | +817%Best | |
| $4B | 11.4 | - | +68% | |
| $2B | 10.0 | 0.06Best | +40% | |
| $39B | 27.9 | - | +183% | |
| $2B | 11.4 | - | +431% | |
| $1B | 21.1 | 1.18 | -7% | |
| $3B | 83.4 | - | +194% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ALKS Historical P/E Data (2006–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $35.39 | $0.90 | 39.3x | -49% |
| FY2025 Q4 | Dec 31 2025 | $27.98 | $1.43 | 19.6x | -75% |
| FY2025 Q3 | - | $30.00 | $2.02 | 14.9x | -81% |
| FY2025 Q2 | Jun 30 2025 | $28.61 | $2.08 | 13.8x | -82% |
| FY2025 Q1 | Mar 31 2025 | $33.02 | $2.09 | 15.8x | -80% |
| FY2024 Q4 | - | $28.76 | $2.17 | 13.3x | -83% |
| FY2024 Q3 | Sep 30 2024 | $27.99 | $1.95 | 14.4x | -81% |
| FY2024 Q2 | Jun 30 2024 | $24.10 | $1.68 | 14.3x | -81% |
| FY2024 Q1 | Mar 31 2024 | $27.07 | $2.53 | 10.7x | -86% |
| FY2023 Q4 | Dec 31 2023 | $27.74 | $2.07 | 13.4x | -83% |
| FY2023 Q3 | Sep 30 2023 | $28.01 | $1.24 | 22.6x | -71% |
| FY2023 Q2 | Jun 30 2023 | $31.30 | $0.57 | 54.9x | -29% |
| FY2013 Q4 | - | $40.66 | $0.13 | 302.5x | +292% |
| FY2013 Q3 | Sep 30 2013 | $33.62 | $0.13 | 250.1x | +224% |
| FY2013 Q2 | Jun 30 2013 | $28.68 | $0.06 | 467.1x | +506% |
| FY2013 Q1 | Mar 31 2013 | $23.70 | $0.18 | 130.7x | +69% |
| FY2009 Q3 | Sep 30 2009 | $9.19 | $0.84 | 11.0x | -86% |
| FY2009 Q2 | - | $10.82 | $0.95 | 11.4x | -85% |
| FY2009 Q1 | - | $12.13 | $1.37 | 8.9x | -89% |
| FY2008 Q4 | Dec 31 2008 | $10.65 | $1.32 | 8.1x | -90% |
| FY2008 Q3 | - | $13.30 | $1.77 | 7.5x | -90% |
| FY2008 Q2 | Jun 30 2008 | $12.36 | $1.82 | 6.8x | -91% |
| FY2008 Q1 | Mar 31 2008 | $11.88 | $1.59 | 7.5x | -90% |
| FY2007 Q4 | Dec 31 2007 | $15.59 | $1.81 | 8.6x | -89% |
| FY2007 Q3 | Sep 30 2007 | $18.40 | $0.21 | 86.0x | +12% |
| FY2007 Q2 | Jun 30 2007 | $14.60 | $0.18 | 79.3x | +3% |
| FY2007 Q1 | Mar 31 2007 | $15.44 | $0.09 | 164.3x | +113% |
| FY2006 Q4 | Dec 31 2006 | $13.37 | $0.15 | 87.0x | +13% |
| FY2006 Q3 | Sep 30 2006 | $15.85 | $0.13 | 118.5x | +54% |
| FY2006 Q2 | Jun 30 2006 | $18.92 | $0.21 | 88.5x | +15% |
| FY2006 Q1 | Mar 31 2006 | $22.05 | $0.07 | 299.2x | +288% |
Average P/E for displayed period: 77.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALKS — Frequently Asked Questions
Quick answers to the most common questions about buying ALKS stock.
What is ALKS's P/E ratio?
Alkermes plc (ALKS) trailing twelve-month P/E ratio is 38.6x, based on TTM diluted EPS of $0.92. The 5-year average P/E is 71.8x and the historical range spans 8.1x to 467.1x.
Is ALKS stock overvalued or undervalued?
ALKS trades at 38.6x P/E, below its 5-year average of 71.8x. At the 70th percentile of its historical range (8.1x–467.1x), the stock is priced at a discount to its own history.
Is ALKS stock expensive?
No, ALKS is not expensive on a historical basis. The current P/E of 38.6x is below the 5-year average of 71.8x and sits at the 70th percentile of its valuation range.
What is ALKS's historical P/E range?
Over the past 5 years, ALKS's P/E ratio has ranged from 8.1x to 467.1x, with a median of 14.9x and an average of 71.8x. The current P/E of 38.6x places the stock at the 70th percentile of this range. Full historical data spans 2006–2026.
How does ALKS's P/E compare to the S&P 500?
ALKS trades at 38.6x P/E versus the S&P 500 median of 25.9x. The 49% premium to the market typically reflects higher expected earnings growth or quality.
How does ALKS's valuation compare to Healthcare peers?
Alkermes plc P/E of 38.6x compares to the Healthcare sector median of 23.4x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ALKS's PEG ratio?
ALKS PEG ratio is N/A, based on a P/E of 38.6x and EPS growth of -34.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ALKS's earnings yield?
ALKS earnings yield is 2.59%, the inverse of its 38.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.